India, May 12 -- Novo Nordisk A/S (NVO), Monday announced data from the phase 3 REAL8 basket study, a part of the ongoing REAL clinical trial, evaluating the efficacy and safety of once-weekly Sogroya in children with growth disorders.
The study revealed that Sogroya was well-tolerated in participants, with no safety or tolerability issues identified compared to once daily growth hormone.
The trial showed that after 52 weeks, once-weekly Sogroya had similar clinical outcomes and safety profile to once-daily Norditropin in children born small for gestational age, or with Noonan syndrome, or with idiopathic short stature.
Additionally, the trial achieved its primary endpoints for the first three sub-studies, demonstrating that once-weekly ...